TY - JOUR
T1 - Immunterapi til patienter med malignt melanom og hjernemetastaser
AU - Simonsen, Line Thing
AU - Schmidt, Anne Mette Sjørslev
AU - Øllegaard, Trine Heide
AU - Svane, Inge Marie
AU - Bastholt, Lars
AU - Luczak, Adam Andrzej
AU - Schmidt, Henrik
PY - 2019/6/10
Y1 - 2019/6/10
N2 - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.
AB - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.
UR - http://www.scopus.com/inward/record.url?scp=85069267455&partnerID=8YFLogxK
M3 - Tidsskriftartikel
C2 - 31267950
SN - 0041-5782
VL - 181
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
M1 - V01190057
ER -